MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Homology Medicines Operating Expenses 2011-2026 | FIXX
Annual Operating Expenses Homology Medicines
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.8 M | 66.1 M | 136 M | 130 M | 133 M | 112 M | 65.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 136 M | 36.8 M | 97 M |
Quarterly Operating Expenses Homology Medicines
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.58 M | 9.17 M | 12.2 M | - | 18.8 M | 17.9 M | 14.8 M | - | 9.66 M | 10.5 M | 28.3 M | - | 33.7 M | 29.1 M | 38.4 M | - | 32.3 M | 32.7 M | 30.4 M | - | 28.8 M | 36.3 M | 37.1 M | - | 31.7 M | 28.4 M | 25.4 M | - | 17.2 M | 14.8 M | 11.8 M | - | 6.66 M | 6.04 M | 4.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.4 M | 4.69 M | 21.3 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.77 | 1.68 % | $ 1.02 B |  USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.92 | 3.05 % | $ 6.76 M | China |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.44 | 2.16 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
343 M | $ 2.02 | 5.76 % | $ 420 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Galectin Therapeutics
GALT
|
20.1 M | $ 2.42 | 3.65 % | $ 155 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Heron Therapeutics
HRTX
|
281 M | $ 1.26 | 6.3 % | $ 210 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
ImmuCell Corporation
ICCC
|
9.8 M | $ 8.28 | -0.84 % | $ 74.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
InflaRx N.V.
IFRX
|
52.4 M | $ 1.53 | 3.38 % | $ 152 M | Germany |
 |
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 103.31 | -2.04 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.14 | 1.47 % | $ 443 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 23.57 | 1.33 % | $ 3 B | USA |
 |
Innate Pharma S.A.
IPHA
|
63 M | $ 1.39 | 0.72 % | $ 235 M | France |
 |
Inventiva S.A.
IVA
|
36.2 M | $ 5.18 | 0.49 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
36 M | $ 0.36 | -8.39 % | $ 840 K | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.46 | 1.04 % | $ 389 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
KalVista Pharmaceuticals
KALV
|
161 M | $ 20.08 | 2.29 % | $ 1.08 B | Britain |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.99 | 2.05 % | $ 4.92 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
8.82 M | $ 12.42 | 1.26 % | $ 1.65 B |  Australia |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |